I am still a bit bemused by the wording of the announcement.
”FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission”
Note - not “data”, not “new information”, but “consideration”.
Were the FDA head honchos having a round of golf, and decided amongst themselves that they had been a bit hard on the Aussie battler? Then back to the clubhouse for a scotch or three.
Or perhaps Big Pharma have “advised” the FDA top order that Meso's gonads have been squeezed enough, so give them a win that also allows BP to make a cheap TO?
Don't get me wrong. My wife is very happy to see the reverse in fortunes, and so quick after that dilutive capital raise too!
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-451
-
-
- There are more pages in this discussion • 642 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B |
Open | High | Low | Value | Volume |
$1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 61090 | $1.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 239558 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 61090 | 1.015 |
1 | 700 | 1.010 |
9 | 123952 | 1.005 |
34 | 516697 | 1.000 |
1 | 25000 | 0.995 |
Price($) | Vol. | No. |
---|---|---|
1.030 | 17500 | 1 |
1.035 | 54000 | 2 |
1.040 | 41250 | 2 |
1.045 | 68050 | 4 |
1.050 | 45395 | 3 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online